Everolimus (EVE) + letrozole (LET) in patients (pts) with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4
2020 ◽
Vol 20
(2)
◽
pp. e173-e180
◽
2019 ◽
2020 ◽
2016 ◽
Vol 4
(4)
◽
pp. 648-654
◽
2020 ◽